TD Cowen Starts Coverage on C4 Therapeutics with a Buy Rating

TD Cowen initiates C4 Therapeutics with a Buy rating, highlighting its strong clinical validation in targeted protein degradation and the potential of Cemsi as a "backbone therapy" for multiple myeloma.